Loading clinical trials...

Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma

Phase 2 Trial of T-cell Based Low-dose Cyclophosphamide and Outpatient Intravenous Interleukin-2 in Metastatic Melanoma

NCT01833767•Western Regional Medical Center

Summary

The purpose of this study is to determine response rates by administering low dose cyclophosphamide on day 1, followed by 5 days of outpatient IL2.

Detailed Description

To determine the response rate, median duration of response and median survival of patients treated with this low-dose cyclophosphamide + moderate dose bolus Interleukin-2 schedule.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients must have a histologic diagnosis of metastatic melanoma. Patients may have received prior systemic therapy or may be previously untreated.
•2. Patients must have measurable disease on physical exam or radiologic studies.
•3. ECOG performance status of 0 or 1 and estimated survival of at least 3 months.
•4. White blood count of \> 3500/mm3, platelet count \> 100,000/mm3, hemoglobin \> 9.0 gm/dl; bilirubin, ALT, AST \< 3 x upper limit of normal; serum creatinine \< 2.0 mg/dl.
•5. Patients must undergo a low-level cardiac stress test as a screen for possible atherosclerotic heart disease. Patients with a positive stress test would be excluded from this trial.
•6. Patients with elevated temperatures \> 100.5 F must have sources of occult infection excluded.
•7. Patients must be felt to have recovered from effects of prior therapy, such as \> 2 weeks after prior chemotherapy.
•8. Women of childbearing potential must have a negative pregnancy test and adequate precautions to prevent pregnancy during treatment must be taken.
•9. Patient consent must be obtained prior to entrance onto study.

Exclusion Criteria

•1\. Medical illness requiring corticosteroids or other immunosuppressive agents (such as cyclosporin or methotrexate.
•2\. Autoimmune disease such as inflammatory arthritis which could be exacerbated by immune-based therapy.
•3\. Prior history of psychiatric disorder which could be exacerbated by interleukin-2.
•4\. Lactation or pregnancy.
•5\. Evidence of significant cardiovascular disease including history of recent (\< 6 months prior) myocardial infarction, congestive heart failure, primary cardiac arrhythmias (not due to electrolyte disorder or drug toxicity, for example) beyond occasional PVC's, angina, positive low-level stress test, or cerebrovascular accident.
•6\. Current untreated brain metastasis.

Locations (1)

Western Regional Medical Center Inc

Goodyear, Arizona, United States

Key Dates

Start Date

October 1, 2012

Primary Completion Date

December 1, 2015

Completion Date

December 1, 2015

Last Updated

August 24, 2017

Conditions

Metastatic Melanoma

Interventions

Cyclophosphamide and Interleukin 2

DRUG

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITINGPHASE1/PHASE2

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

NCT06975293

Metastatic Non-small Cell Lung CancerMetastatic Melanoma+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 24, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3